BioCentury
ARTICLE | Clinical News

Reolysin: Completed Phase II enrollment

July 21, 2014 7:00 AM UTC

Oncolytics said NIH’s NCI completed enrollment of 70 patients in the open-label, U.S. Phase II OSU-10045 trial comparing carboplatin and paclitaxel on day 1 plus IV Reolysin on days 1-5 of 21-day cycles vs. carboplatin and paclitaxel. Oncolytics is providing clinical supplies of Reolysin for the trial. ...